In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...
Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...
After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...
It has been about a month since the last earnings report for Recursion Pharmaceuticals (RXRX). Shares have added about 6.5% in that time frame, outperforming the S&P 500. But investors have to be ...
The General specializes in auto coverage policies for drivers who are high risk or who have poor credit scores. It offers affordable car insurance with low down payments and is geared toward those who ...
2026 Maine Senate - Collins vs. Platner Pan Atlantic Platner 43, Collins 42 Platner +1 2026 Maine Senate - Collins vs. Mills Pan Atlantic Collins 43, Mills 43 Tie 2026 California Governor - Open ...
THE first edition of this admirable and well-known treatise was the single-handed work of Prof. Whittaker, and was published in 1902. Into the second edition, which was published thirteen years later ...
National General, formerly known as GMAC insurance, sells homeowners insurance as well as RV and auto insurance. Plan coverage with National General ranges from basic to comprehensive. National ...
Analyzing stochastic cell-to-cell variability can potentially reveal causal interactions in gene regulatory networks.
Alexandra Twin has 15+ years of experience as an editor and writer, covering financial news for public and private companies. David Kindness is a Certified Public Accountant (CPA) and an expert in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback